Video Content above is prompted by the following:
- How does inclusion of chemotherapy affect the adverse event profile? In the ARASENS trial (NCT02799602), authors concluded that many of the adverse effects were consistent with those observed in previous studies with docetaxel. Is this consistent with what you see in clinical practice?